
Media Center
Filter by:
July 05, 2021
Phase 1 safety and tolerability study of IMB-1018972, a novel oral modulator of substrate utilization designed to improve cardiac metabolic efficiency and bioenergetics
June 22, 2021
Imbria Pharmaceuticals announces enrolment of the first 10 patients in IMPROVE-DiCE, an exploratory Phase 2 study investigating the impact of IMB-1018972 on cardiac energetics, metabolism and function in patients with type 2 diabetes
May 17, 2021